ହାଇଡ୍ରୋମର୍ଫୋନ

ହାଇଡ୍ରୋମର୍ଫୋନ
Clinical data
Trade names	Dilaudid, Hydromorph Contin, Palladone, others
Synonyms	Dihydromorphinone
AHFS/Drugs.com	monograph
MedlinePlus	a682013
data	US DailyMed: Hydromorphone;
Pregnancy; category	AU: C ; US: N (Not classified yet) ; ;
Dependence; liability	High
Routes of; administration	By mouth, intramuscular, intravenous, subcutaneous
ATC code	N02AA03 (WHO) ;
Legal status
Legal status	AU: S8 (Controlled) ; CA: Schedule I ; DE: Anlage III (Prescription only) ; NZ: Class B ; UK: Class A and Classified Drug; US: Schedule II ; UN: Narcotic Schedule I ;
Pharmacokinetic data
Bioavailability	By mouth: 30–35%, Intranasal: 52–58%, IV/IM: 100%
Protein binding	20%
Metabolism	Liver
Onset of action	15 to 30 min
Elimination half-life	2–3 hours
Duration of action	4 to 5 hrs
Excretion	Kidney
Identifiers
	IUPAC name 4,5-α-Epoxy-3-hydroxy-17-methyl morphinan-6-one;
CAS Number	466-99-9 ;
PubChem CID	5284570;
IUPHAR/BPS	7082;
DrugBank	DB00327 ;
ChemSpider	4447624 ;
UNII	Q812464R06;
KEGG	D08047 ;
ChEBI	CHEBI:5790 ;
ChEMBL	CHEMBL398707 ;
ECHA InfoCard	100.006.713
Chemical and physical data
Formula	C17H19NO3
Molar mass	୨୮୫.୩୪ g·mol−1
3D model (JSmol)	Interactive image;
Solubility in water	HCl salt: 333 mg/mL (20 °C)
	SMILES O=C4[C@@H]5Oc1c2c(ccc1O)C[C@H]3N(CC[C@]25[C@H]3CC4)C;
	InChI InChI=1S/C17H19NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2,4,10-11,16,19H,3,5-8H2,1H3/t10-,11+,16-,17-/m0/s1 ; Key:WVLOADHCBXTIJK-YNHQPCIGSA-N ;
(verify)

ହାଇଡ୍ରୋମର୍ଫୋନ (ନାମ ଡିହାଇଡ୍ରୋମରଫିନନ, ବିକ୍ରୟ ନାମ ଡିଲାଉଡିଡ୍) ହୋଇଥିଲା, ଏକ ଅଫିମ ଜାତୀୟ ଔଷଧ ଯାହା ମଧ୍ୟମରୁ ପ୍ରବଳ ଧରଣର ଯନ୍ତ୍ରଣାର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ | ^[୪] ଦୀର୍ଘକାଳୀନ କର୍କଟ ଯନ୍ତ୍ରଣା ପାଇଁ ଏହ ବ୍ୟବହାର କରିବାକୁ ସୁପାରିଶ କରାଯାଏ | ^[୬] ଏହା ପାଟିରେ ଦିଆଯାଏ କିମ୍ବା ମାଂସପେଶୀ, ଚର୍ମ ତଳେ ବା ଶିରାଭ୍ୟନ୍ତରରେ ଇଞ୍ଜେକ୍ସନ ଆକାରରେ ବ୍ୟବହୃତ ହୋଇପାରେ | ^[୪] ଏହାର ପ୍ରଭାବ ସାଧାରଣତଃ ଅଧ ଘଣ୍ଟା ମଧ୍ୟରେ ଆରମ୍ଭ ହୋଇ ପାଞ୍ଚ ଘଣ୍ଟା ପର୍ଯ୍ୟନ୍ତ ରହିଥାଏ | ^[୪]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ମୁଣ୍ଡ ବୁଲାଇବା, ନିଦ୍ରାହୀନତା, ବାନ୍ତି, ଅଇ, ଗଲୁ ଏବଂ କୋଷ୍ଠକାଠିନ୍ୟ ହୋଇପାରେ | ^[୪] ଗୁରୁତର ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଅପବ୍ୟବ‌ହାର, ନିମ୍ନ ରକ୍ତଚାପ, ବାତ, ଶ୍ୱାସକ୍ରିୟା କମିଯିବା ଏବଂ ସେରୋଟୋନିନ୍ ସିଣ୍ଡ୍ରୋମ ହୋଇପାରେ । ^[୪] ଏହାର ମାତ୍ରା ଶୀଘ୍ର ହ୍ରାସ କରିଦେଲେ ଓପିଅଏଡ ପ୍ରତ୍ୟାହାର ହୋଇପାରେ | ^[୪] ଗର୍ଭାବସ୍ଥାରେ କିମ୍ବା ସ୍ତନ୍ୟପାନ ସମୟରେ ବ୍ୟବହାର କରିବା ପରାମର୍ଶ ଦିଆଯାଇନଥାଏ | ^[୭] ମୁଖ୍ୟତଃ ମସ୍ତିଷ୍କ ଏବଂ ମେରୁଦଣ୍ଡରେ ଥିବା ଓପିଅଏଡ ରିସେପ୍ଟରଗୁଡ଼ିକ ସକ୍ରିୟ କରି ହାଇଡ୍ରୋମୋର୍ଫୋନ କାମ କରେ ବୋଲି ବିଶ୍ୱାସ କରାଯାଏ | ^[୪] ପାଟିରେ ଦିଆଯାଉଥିବା ଦୁଇ ମିଗ୍ରା ହାଇଡ୍ରୋମୋର୍ଫୋନ୍ ପ୍ରାୟ ୧୦ ମିଗ୍ରା ମର୍ଫିନ ସ‌ହିତ ସମାନ । ^[୮]

ହାଇଡ୍ରୋମର୍ଫୋନ ପେଟେଣ୍ଟ ହୋଇଥିଲା ୧୯୨୩ ମସିହାରେ । ^[୯] ଏହା ଏକ ଜେନେରିକ ଔଷଧ ଭାବରେ ଉପଲବ୍ଧ | ^[୪] ଯୁକ୍ତରାଜ୍ୟରେ ଦୁଇ ମିଗ୍ରା ବଟିକା ପାଇଁ ୨୦୧୯ ସୁଦ୍ଧା ଏନଏଚଏସ £୦.୩୨ ଖର୍ଚ୍ଚ କରେ ।^[୮] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ପରିମାଣର ହୋଲସେଲ ମୂଲ୍ୟ ପ୍ରାୟ ୦.୦୭ ଡଲାର ଅଟେ । ^[୧୦] ୨୦୧୭ରେ ଏହା ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ୨୦୫ତମ ସାଧାରଣ ପ୍ରେସକ୍ରିପସନ ଔଷଧ ଥିଲା, ଯାହାର ଦୁଇ ଲକ୍ଷରୁ ଅଧିକ ପ୍ରେସକ୍ରିପସନ୍ ରହିଥିଲା। ^[୧୧] ^[୧୨] ହାଇଡ୍ରୋମୋର୍ଫୋନ୍ ମୋର୍ଫାଇନ୍ରୁ ତିଆରି ହୋଇଥାଏ | ^[୧୩]

ଆଧାର

↑ Bonewit-West, Kathy; Hunt, Sue A.; Applegate, Edith (2012). Today's Medical Assistant: Clinical and Administrative Procedures (in ଇଂରାଜୀ). Elsevier Health Sciences. p. 571. ISBN 9781455701506.
↑ ^୨.୦ ^୨.୧ "Hydromorphone Use During Pregnancy". Drugs.com. 19 November 2019. Retrieved 16 May 2020.
↑ Coda BA, Rudy AC, Archer SM, Wermeling DP (July 2003). "Pharmacokinetics and bioavailability of single-dose intranasal hydromorphone hydrochloride in healthy volunteers". Anesth. Analg. 97 (1): 117–23, table of contents. CiteSeerX 10.1.1.551.6509. doi:10.1213/01.ANE.0000066311.40978.4F. PMID 12818953. S2CID 22694749.
↑ ^୪.୦୦ ^୪.୦୧ ^୪.୦୨ ^୪.୦୩ ^୪.୦୪ ^୪.୦୫ ^୪.୦୬ ^୪.୦୭ ^୪.୦୮ ^୪.୦୯ "Hydromorphone Hydrochloride Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). American Society of Health-System Pharmacists. Retrieved 15 April 2019.
↑ Vallner JJ, Stewart JT, Kotzan JA, Kirsten EB, Honigberg IL (April 1981). "Pharmacokinetics and bioavailability of hydromorphone following intravenous and oral administration to human subjects". J Clin Pharmacol. 21 (4): 152–6. doi:10.1002/j.1552-4604.1981.tb05693.x. PMID 6165742. S2CID 29864565.
↑ British national formulary: BNF 76 (76 ed.). Pharmaceutical Press. 2018. pp. 24, 456. ISBN 9780857113382.
↑ "Hydromorphone Use During Pregnancy". Drugs.com (in ଇଂରାଜୀ). Retrieved 15 April 2019.
↑ ^୮.୦ ^୮.୧ British national formulary: BNF 76 (76 ed.). Pharmaceutical Press. 2018. pp. 24, 456. ISBN 9780857113382.
↑ Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery (in ଇଂରାଜୀ). John Wiley & Sons. p. 526. ISBN 9783527607495.
↑ "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services (in ଇଂରାଜୀ). Archived from the original on 2019-03-06. Retrieved 3 March 2019.
↑ "The Top 300 of 2020". ClinCalc. Retrieved 11 April 2020.
↑ "Hydromorphone Hydrochloride - Drug Usage Statistics". ClinCalc. Archived from the original on 11 April 2020. Retrieved 11 April 2020.
↑ Vardanyan, Ruben; Hruby, Victor (2006). Synthesis of Essential Drugs (in ଇଂରାଜୀ). Elsevier. p. 25. ISBN 9780080462127.

[1] Bonewit-West, Kathy; Hunt, Sue A.; Applegate, Edith (2012). Today's Medical Assistant: Clinical and Administrative Procedures (in ଇଂରାଜୀ). Elsevier Health Sciences. p. 571. ISBN 9781455701506.

[Drugs.com_pregnancy-2] ୨.୦ ^୨.୧ "Hydromorphone Use During Pregnancy". Drugs.com. 19 November 2019. Retrieved 16 May 2020.

[pmid12818953-3] Coda BA, Rudy AC, Archer SM, Wermeling DP (July 2003). "Pharmacokinetics and bioavailability of single-dose intranasal hydromorphone hydrochloride in healthy volunteers". Anesth. Analg. 97 (1): 117–23, table of contents. CiteSeerX 10.1.1.551.6509. doi:10.1213/01.ANE.0000066311.40978.4F. PMID 12818953. S2CID 22694749.

[AHFS2019-4] ୪.୦୦ ^୪.୦୧ ^୪.୦୨ ^୪.୦୩ ^୪.୦୪ ^୪.୦୫ ^୪.୦୬ ^୪.୦୭ ^୪.୦୮ ^୪.୦୯ "Hydromorphone Hydrochloride Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). American Society of Health-System Pharmacists. Retrieved 15 April 2019.

[pmid6165742-5] Vallner JJ, Stewart JT, Kotzan JA, Kirsten EB, Honigberg IL (April 1981). "Pharmacokinetics and bioavailability of hydromorphone following intravenous and oral administration to human subjects". J Clin Pharmacol. 21 (4): 152–6. doi:10.1002/j.1552-4604.1981.tb05693.x. PMID 6165742. S2CID 29864565.

[BNF76-6] British national formulary: BNF 76 (76 ed.). Pharmaceutical Press. 2018. pp. 24, 456. ISBN 9780857113382.

[Preg2019-7] "Hydromorphone Use During Pregnancy". Drugs.com (in ଇଂରାଜୀ). Retrieved 15 April 2019.

[autogen1-8] ୮.୦ ^୮.୧ British national formulary: BNF 76 (76 ed.). Pharmaceutical Press. 2018. pp. 24, 456. ISBN 9780857113382.

[Fis2006-9] Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery (in ଇଂରାଜୀ). John Wiley & Sons. p. 526. ISBN 9783527607495.

[NADAC2019-10] "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services (in ଇଂରାଜୀ). Archived from the original on 2019-03-06. Retrieved 3 March 2019.

[ref-11] "The Top 300 of 2020". ClinCalc. Retrieved 11 April 2020.

[ref1-12] "Hydromorphone Hydrochloride - Drug Usage Statistics". ClinCalc. Archived from the original on 11 April 2020. Retrieved 11 April 2020.

[13] Vardanyan, Ruben; Hruby, Victor (2006). Synthesis of Essential Drugs (in ଇଂରାଜୀ). Elsevier. p. 25. ISBN 9780080462127.

[୨]

[୧]

[୩]

[୪]

[୫]

[୬]

[୭]

[୮]

[୯]

[୧୦]

[୧୧]

[୧୨]

[୧୩]